21 results match your criteria: "University of California Los Angeles (G.C.F.).[Affiliation]"
Home-Time, Mortality, and Readmissions Among Patients Hospitalized With Heart Failure: A Baseline Prior to IMPLEMENT-HF.
Circ Heart Fail
October 2024
Division of Cardiology, Department of Medicine, University of California Los Angeles (G.C.F.).
Article Synopsis
- Home-time is the time patients spend alive and at home after being treated for heart failure, and it hasn't been studied much before. * -
- The study looked at 66,019 older patients who had heart failure from 2019 to 2021 and found that many didn’t get to spend all their time at home; only 22% spent a full year at home after leaving the hospital. * -
- A lot of older patients, especially Black patients, had less time at home, and many faced high rates of returning to the hospital or dying within a year after their discharge.*
Equity in Heart Failure Care: A Get With the Guidelines Analysis of Between- and Within-Hospital Differences in Care by Sex, Race, Ethnicity, and Insurance.
Circ Heart Fail
October 2024
Division of Cardiology and the Cardiovascular Institute (A.T.S., F.R., P.A.H.), Stanford University, CA.
Article Synopsis
- Disparities in heart failure care quality contribute to varying patient outcomes based on sex, race, ethnicity, and insurance type among hospitalized patients.
- A study analyzed data from 685,227 patients across 596 hospitals, finding that women generally received worse quality of care than men, but some differences disappeared after adjusting for individual patient factors.
- Racial and ethnic minorities often performed as well or better than White and insured patients, but specific treatment measures showed significant gaps, particularly for certain groups like Asian, Hispanic, and Black patients, highlighting within-hospital variations and a need for improvement in care equity.
Twenty Years of Get With The Guidelines-Stroke: Celebrating Past Successes, Lessons Learned, and Future Challenges.
Stroke
June 2024
Department of Neurology and Bioinformatics and Data Sciences (L.H.S.), Yale School of Medicine, New Haven, CT.
Article Synopsis
- The Get With The Guidelines-Stroke program is a major U.S. disease registry that has been improving stroke care and patient outcomes for 20 years.
- This narrative review covers the program's history, key achievements, and significant impacts on stroke care.
- It also explores future challenges and opportunities for enhancing the program over the next two decades.
Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients With Atrial Fibrillation in the United States.
Circ Cardiovasc Qual Outcomes
December 2023
Section of Cardiology, Denver VA Medical Center, Aurora, CO (A.S., P.M.H., P.D.V., P.L.H.).
Background: Among patients hospitalized for atrial fibrillation, the frequency of off-label direct oral anticoagulant (DOAC) dosing, associated factors, hospital-level variation, and temporal trends in contemporary practice are unknown.
Methods: Using the Get With The Guidelines-Atrial Fibrillation registry, patients admitted from January 1, 2014, to March 31, 2020, and discharged on DOACs were stratified according to receipt of underdosing, overdosing, or recommended dosing. Factors associated with off-label dosing (defined as underdosing or overdosing) were identified using logistic regression.
STRONG-HF and Implementing Heart Failure Therapies: Godspeed … With Care.
Circulation
April 2023
Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, University of California Los Angeles (G.C.F.).
Assessing Heuristic Bias During Care for Patients Hospitalized for Heart Failure: Get With The Guidelines-Heart Failure.
Circ Heart Fail
February 2023
Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA (D.L.B.).
Background: Heuristic biases are increasingly recognized, and potentially modifiable, contributors to patient care and outcomes. Left digit bias is a cognitive bias where continuous variables are categorized by their left-most digit. The impact of this heuristic bias applied to patient age on quality of care in heart failure has not been explored.
View Article and Find Full Text PDFAdoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry.
Circ Heart Fail
January 2023
Department of Medicine (J.B.P., R.J.M., E.C.O., S.J.G.), Duke University School of Medicine, Durham, NC.
Cardiac Rehabilitation and the COVID-19 Pandemic: Persistent Declines in Cardiac Rehabilitation Participation and Access Among US Medicare Beneficiaries.
Circ Cardiovasc Qual Outcomes
December 2022
Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA (M.S.V., Y.S., J.X., R.W.Y., D.S.K.).
Background: The impact of the COVID-19 pandemic on participation in and availability of cardiac rehabilitation (CR) is unknown.
Methods: Among eligible Medicare fee-for-service beneficiaries, we evaluated, by month, the number of CR sessions attended per 100 000 beneficiaries, individuals eligible to initiate CR, and centers offering in-person CR between January 2019 and December 2021. We compared these outcomes between 2 periods: December 1, 2019 through February 28, 2020 (period 1, before declaration of the pandemic-related national emergency) and October 1, 2021 through December 31, 2021 (period 2, the latest period for which data are currently available).
Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials.
Circ Heart Fail
August 2020
American Heart Association, Dallas, TX (M.J.).
Background: Gender disparities in authorship of heart failure (HF) guideline citations and clinical trials have not been examined.
Methods: We identified authors of publications referenced in Class I Recommendations in United States (n=173) and European (n=100) HF guidelines and of publications of all HF trials with >400 participants (n=118) published between 2001 and 2016. Authors' genders were determined, and changes in authorship patterns over time were evaluated with linear regression and nonparametric testing.
Procedural Patterns and Safety of Atrial Fibrillation Ablation: Findings From Get With The Guidelines-Atrial Fibrillation.
Circ Arrhythm Electrophysiol
September 2020
Duke Clinical Research Institute (Z.L., D.N.H., R.A.M., J.P.P.), Duke University Medical Center.
Background: Catheter ablation is an increasingly used treatment for symptomatic atrial fibrillation (AF). However, there are limited prospective, nationwide data on patient selection and procedural characteristics. This study describes patient characteristics, techniques, treatment patterns, and safety outcomes of patients undergoing AF ablation.
View Article and Find Full Text PDFRisk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk.
Circ Heart Fail
June 2020
Department of Medicine, University of Mississippi Medical Center, Jackson (J.B.).
Role of Data Registries in the Time of COVID-19.
Circ Cardiovasc Qual Outcomes
May 2020
American Heart Association, Dallas, TX (H.M.A., J.H.W., J.G.W., M.B., C.R.).
Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.
Circulation
December 2019
Inova Heart and Vascular Institute, Falls Church, VA (L.B.C., C.M.O.).
Following regulatory guidance set forth in 2008 by the US Food and Drug Administration for new drugs for type 2 diabetes mellitus, many large randomized, controlled trials have been conducted with the primary goal of assessing the safety of antihyperglycemic medications on the primary end point of major adverse cardiovascular events, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Heart failure (HF) was not specifically mentioned in the US Food and Drug Administration guidance and therefore it was not a focus of these studies when planned. Several trials subsequently showed the impact of antihyperglycemic drugs on HF outcomes, which were not originally specified as the primary end point of the trials.
View Article and Find Full Text PDFThirty-Day Readmissions After Hospitalization for Hypertensive Emergency.
Hypertension
January 2019
Brigham and Women's Hospital Heart and Vascular Center, Boston, MA (M.V., D.L.B.).
Hypertensive emergency is a clinical entity with potentially serious health implications and high healthcare utilization. There is a lack of nationally representative data on incidence, causes, and predictors of 30-day readmission after hospitalization for hypertensive emergency. We used the 2013 to 2014 Nationwide Readmissions Database to identify index hospitalizations for hypertensive emergency.
View Article and Find Full Text PDFAdverse Change in Employment Status After Acute Myocardial Infarction: Analysis From the TRANSLATE-ACS Study.
Circ Cardiovasc Qual Outcomes
June 2018
Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC (H.J.W., E.D.P., T.Y.W.). Duke Clinical Research Institute, Durham, NC (H.J.W., L.A.K., E.D.P., T.Y.W.). Cardiology Division, Department of Medicine, University of California Los Angeles (G.C.F.).
Background: Inability to resume employment after acute myocardial infarction (MI) has important implications for patients. We sought to assess the prevalence of and outcomes associated with adverse change in employment after MI in a national US cohort.
Methods And Results: The TRANSLATE-ACS study (Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome) assessed employment status at baseline and 1 year among 9319 patients with MI (mean age, 60.
Availability and Use of Shared Data From Cardiometabolic Clinical Trials.
Circulation
February 2018
Division of Cardiology, Stony Brook University, NY (J.B.).
Background: Sharing of patient-level clinical trial data has been widely endorsed. Little is known about how extensively these data have been used for cardiometabolic diseases. We sought to evaluate the availability and use of shared data from cardiometabolic clinical trials.
View Article and Find Full Text PDFDose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis.
Circ Heart Fail
August 2017
From the John H. Stroger Jr Hospital of Cook County, Chicago, IL (M.S.K.); University of California Los Angeles (G.C.F.); Veterans Affairs Medical Center and George Washington University, DC (A.A.); Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, NC (S.J.G.); Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.V.); Emory University, Atlanta, GA (H.K.); University of Georgia, Athens (C.M.); Northwestern University Feinberg School of Medicine, Chicago, IL (M.G.); and Stony Brook University, NY (J.B.).
Background: The association between angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) doses on outcomes in patients with heart failure (HF) with reduced ejection fraction is uncertain. The objective of this study was to investigate the effect of dose of ACEI and ARBs on outcomes and drug discontinuation in patients with HF with reduced ejection fraction.
Methods And Results: MEDLINE, Ovid SP, and Embase were searched from the inception of these databases till August 2016.
Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling.
Circulation
October 2016
From the Division of Cardiology, Duke University Medical Center, Durham, NC (S.D.P., J.P.P., E.D.P.); Duke Clinical Research Institute, Durham, NC (S.D.P., P.S., L.T., J.P.P., E.D.P.); Division of Cardiology, University of California Los Angeles (G.C.F.); Lankenau Institute for Medical Research, Wynnewood, PA (P.R.K.); Harvard Medical School, Massachusetts General Hospital, Boston (D.E.S.); Hofstra North Shore/Long Island School of Medicine, Hempstead, NY (J.A.); Mayo Clinic College of Medicine, Rochester, MN (BJ.G.); Department of Medicine, Stanford University School of Medicine, Palo Alto, CA (K.W.M.); Boston University School of Medicine, Boston, MA (E.M.H.); and Kaiser Permanente, Oakland, CA (A.S.G.).
Distinct Short-Term Outcomes in Patients With Mild Versus Rapidly Improving Stroke Not Treated With Thrombolytics.
Stroke
May 2016
From the Department of Neurology, University of Miami Miller School of Medicine, FL (J.G.R., H.G., I.C.-B., R.L.S.); Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada (E.E.S.); Duke Clinical Research Institute, Durham, NC (L.L.); Neuroscience Institute, University of Cincinnati, Cincinnati, OH (P.K.); Division of Cardiology, Department of Internal Medicine, Brigham and Women's Hospital Heart & Vascular Center/Harvard Medical School, Boston, MA (D.L.B.); Division of Cardiology, Department of Internal Medicine, University of California Los Angeles (G.C.F.); and Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston (L.H.S.).
Background And Purpose: Mild stroke (MS) and rapidly improving stroke (RIS) symptoms are common stroke presentations. Our objective is to describe the short-term outcomes in this population.
Methods: A retrospective analysis of patients with ischemic stroke in the Get With The Guidelines-Stroke registry who arrived ≤4.
Unplanned Inpatient and Observation Rehospitalizations After Acute Myocardial Infarction: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Circulation
February 2016
From Duke Clinical Research Institute, Durham, NC (C.N.H., T.Y.W., L.A.M., E.P.P.); Division of Cardiology, University of Colorado School of Medicine, Aurora, CO (J.C.M.); Lilly USA LLC, Indianapolis, IN (M.B.E., M.E.Z.); Cedars Sinai Heart Institute, Los Angeles, CA (T.D.H.); and Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.).
Background: Previous studies examining early readmission after acute myocardial infarction have focused exclusively on inpatient readmissions. However, from a patient's perspective, any unplanned inpatient or observation rehospitalization after acute myocardial infarction represents a significant event; these unplanned rehospitalizations have not been well characterized.
Methods And Results: We examined all patients with acute myocardial infarction treated with percutaneous coronary intervention and discharged alive from 233 hospitals in the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) study from 2010 to 2012.
Early Medication Nonadherence After Acute Myocardial Infarction: Insights into Actionable Opportunities From the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Circ Cardiovasc Qual Outcomes
July 2015
From the Duke Clinical Research Institute, Durham, NC (R.M., E.D.P., E.H., T.Y.W.); National Health Centre Singapore, Singapore, Singapore (C.T.C.); Lilly, USA, LLC, Indianapolis (M.B.E., M.Z.); Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles (G.C.F.); and Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital (T.D.H.).
Background: Nonadherence to prescribed evidence-based medications after acute myocardial infarction (MI) can contribute to worse outcomes and higher costs. We sought to better understand the modifiable factors contributing to early nonadherence of evidence-based medications after acute MI.
Methods And Results: We assessed 7425 acute MI patients treated with percutaneous coronary intervention at 216 US hospitals participating in TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) between April 2010 and May 2012.